GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Piotroski F-Score

Absci (ABSI) Piotroski F-Score : 4 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Absci has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Absci's Piotroski F-Score or its related term are showing as below:

ABSI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 4

During the past 5 years, the highest Piotroski F-Score of Absci was 4. The lowest was 2. And the median was 3.


Absci Piotroski F-Score Historical Data

The historical data trend for Absci's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Piotroski F-Score Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 3.00 4.00 3.00

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 4.00 2.00 3.00 4.00

Competitive Comparison of Absci's Piotroski F-Score

For the Biotechnology subindustry, Absci's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Absci's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Absci's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -41.672 + -21.994 + -23.545 + -21.975 = $-109.19 Mil.
Cash Flow from Operations was -19.234 + -10.361 + -14.922 + -17.863 = $-62.38 Mil.
Revenue was 3.367 + 0.744 + 0.338 + 0.898 = $5.35 Mil.
Gross Profit was 3.367 + 0.744 + 0.338 + 0.898 = $5.35 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(295.808 + 254.153 + 236.344 + 217.298 + 274.898) / 5 = $255.7002 Mil.
Total Assets at the begining of this year (Mar23) was $295.81 Mil.
Long-Term Debt & Capital Lease Obligation was $9.07 Mil.
Total Current Assets was $181.80 Mil.
Total Current Liabilities was $25.29 Mil.
Net Income was -28.68 + -27.259 + -19.471 + -23.355 = $-98.77 Mil.

Revenue was 1.002 + 2.369 + 1.557 + 1.269 = $6.20 Mil.
Gross Profit was 1.002 + 2.369 + 1.557 + 1.269 = $6.20 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(395.46 + 366.315 + 339.387 + 321.008 + 295.808) / 5 = $343.5956 Mil.
Total Assets at the begining of last year (Mar22) was $395.46 Mil.
Long-Term Debt & Capital Lease Obligation was $14.42 Mil.
Total Current Assets was $165.32 Mil.
Total Current Liabilities was $27.20 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Absci's current Net Income (TTM) was -109.19. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Absci's current Cash Flow from Operations (TTM) was -62.38. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-109.186/295.808
=-0.36911105

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-98.765/395.46
=-0.24974713

Absci's return on assets of this year was -0.36911105. Absci's return on assets of last year was -0.24974713. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Absci's current Net Income (TTM) was -109.19. Absci's current Cash Flow from Operations (TTM) was -62.38. ==> -62.38 > -109.19 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=9.07/255.7002
=0.03547123

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=14.418/343.5956
=0.04196212

Absci's gearing of this year was 0.03547123. Absci's gearing of last year was 0.04196212. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=181.798/25.288
=7.18910155

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=165.317/27.201
=6.07760744

Absci's current ratio of this year was 7.18910155. Absci's current ratio of last year was 6.07760744. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Absci's number of shares in issue this year was 99.393. Absci's number of shares in issue last year was 91.479. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5.347/5.347
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=6.197/6.197
=1

Absci's gross margin of this year was 1. Absci's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=5.347/295.808
=0.01807591

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=6.197/395.46
=0.01567036

Absci's asset turnover of this year was 0.01807591. Absci's asset turnover of last year was 0.01567036. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Absci has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Absci  (NAS:ABSI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Absci Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Absci's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660